• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:47:52 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NNVC alert in real time by email
    SC 13G/A 1 tm216476d13_sc13ga.htm SC 13G/A

     

    CUSIP No: 630087302

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    NanoViricides, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    630087302

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No: 630087302

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
    OWNED BY 0
     
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      0

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      0
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
      0%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 630087302

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

    NUMBER OF (5) SOLE VOTING POWER
     
    SHARES 0  
     
    BENEFICIALLY (6) SHARED VOTING POWER **
     
    OWNED BY 0
     
    EACH (7) SOLE DISPOSITIVE POWER
     
    REPORTING 0
     
    PERSON WITH (8) SHARED DISPOSITIVE POWER **
     
      0

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      0
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
      0%
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

    CUSIP No: 630087302

     

    Item 1.

     

    (a)Name of Issuer

     

    NanoViricides, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    1 Controls Drive, Shelton, Connecticut 06484

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)CUSIP Number

     

    630087302

     

     

     

    CUSIP No: 630087302

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.           Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

     

     

    CUSIP No: 630087302

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No: 630087302

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky  
    pursuant to a Limited Power of   Name: Brian Sopinsky  
    Attorney, a copy of which was   Title: Secretary
    previously filed      

     

    By: /s/ Brian Sopinsky    
    Name: Brian Sopinsky    
    Title: Secretary    

     

     

     

    CUSIP No: 630087302

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         
         

    *Previously filed 

     

     

    Get the next $NNVC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NNVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NNVC
    SEC Filings

    View All

    SEC Form 10-Q filed by NanoViricides Inc.

    10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)

    5/15/25 4:31:12 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NanoViricides Inc.

    10-Q - NANOVIRICIDES, INC. (0001379006) (Filer)

    2/14/25 4:30:24 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NanoViricides Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - NANOVIRICIDES, INC. (0001379006) (Filer)

    12/12/24 5:00:49 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

    SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.Event Information:EventNanoViricides Presentation at the Biotech Showcase, San FransiscoDay & DateTuesday, January 14, 2025Time, Track & Room2:30pm PT, Yosemite A (Ballroom Level)LocationHilton San Fransisco - Union SquareAnil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline a

    1/13/25 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

    SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already.This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.In addition to that, in the USA, and globally, there are significant numbers of cases of COVID-19, RSV, and hMPV as expected seasonally, that cause various respiratory syndromes from common colds

    1/8/25 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

    SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug."Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."WHO has stated "Available virus

    12/23/24 6:30:00 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by 10% Owner before reverse split Boniuk Milton

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    1/28/25 3:36:56 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by 10% Owner before reverse split Stephenson Fournier, Pllc

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    1/24/25 11:58:54 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Diwan Anil gifted 94,471 shares, closing all direct ownership in the company

    4 - NANOVIRICIDES, INC. (0001379006) (Issuer)

    8/10/22 6:51:52 PM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NNVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - NANOVIRICIDES, INC. (0001379006) (Subject)

    2/16/21 9:47:52 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care